Ryuji Furihata Selected Research

Schizophrenia (Dementia Praecox)

10/2023	Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study.
7/2023	Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan.
1/2023	Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score-matched analysis.
1/2023	Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project.
12/2022	The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" project.
12/2022	Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia".
11/2022	Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia.
10/2022	Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study.
3/2022	The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project.
1/2022	Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ryuji Furihata Research Topics

Disease

16	Schizophrenia (Dementia Praecox) 10/2023 - 08/2009
8	Major Depressive Disorder (Major Depressive Disorders) 10/2023 - 10/2019
5	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022 - 08/2009
2	Disorders of Excessive Somnolence (Hypersomnia) 04/2023 - 08/2012
2	Mood Disorders (Mood Disorder) 01/2023 - 10/2019
2	Treatment-Resistant Schizophrenia 10/2022 - 01/2022
1	Lymphoma (Lymphomas) 04/2023
1	Kleine-Levin Syndrome (Syndrome, Kleine-Levin) 04/2023
1	Hallucinations (Hallucination) 04/2023
1	Mental Disorders (Mental Disorder) 01/2022
1	Colitis 10/2019

Drug/Important Bio-Agent (IBA)

9	Antipsychotic Agents (Antipsychotics)IBA 10/2023 - 09/2021
5	Anti-Anxiety Agents (Anxiolytics)IBA 10/2023 - 09/2021
5	Hypnotics and Sedatives (Sedatives)IBA 10/2023 - 09/2021
4	Antidepressive Agents (Antidepressants)IBA 01/2023 - 09/2021
4	Indicators and Reagents (Reagents)IBA 01/2023 - 08/2009
3	Cholinergic Antagonists (Anticholinergics)IBA 11/2022 - 01/2022
2	N-acetyltryptophanamide (NATA)IBA 12/2022 - 03/2022
2	Clozapine (Clozaril)FDA LinkGeneric 10/2022 - 01/2022
1	Carnitine (L-Carnitine)FDA LinkGeneric 04/2023
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022
1	Olanzapine (Zyprexa)FDA Link 09/2021
1	Quetiapine Fumarate (Seroquel)FDA Link 09/2021
1	Aripiprazole (Abilify)FDA Link 09/2021
1	Risperidone (Risperdal Consta)FDA LinkGeneric 09/2021
1	blonanserinIBA 09/2021
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2020
1	Dextran SulfateIBA 10/2019
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 08/2012
1	Lysergic Acid Diethylamide (LSD)IBA 08/2012

Therapy/Procedure

5	Therapeutics 10/2023 - 10/2019
4	Drug Therapy (Chemotherapy) 04/2023 - 03/2022
3	Polypharmacy 01/2023 - 09/2021
1	Injections 07/2023